Prioritizing Candidate Disease Metabolites Based on Global Functional Relationships between Metabolites in the Context of Metabolic Pathways

Identification of key metabolites for complex diseases is a challenging task in today's medicine and biology. A special disease is usually caused by the alteration of a series of functional related metabolites having a global influence on the metabolic network. Moreover, the metabolites in the same metabolic pathway are often associated with the same or similar disease. Based on these functional relationships between metabolites in the context of metabolic pathways, we here presented a pathway-based random walk method called PROFANCY for prioritization of candidate disease metabolites. Our strategy not only takes advantage of the global functional relationships between metabolites but also sufficiently exploits the functionally modular nature of metabolic networks. Our approach proved successful in prioritizing known metabolites for 71 diseases with an AUC value of 0.895. We also assessed the performance of PROFANCY on 16 disease classes and found that 4 classes achieved an AUC value over 0.95. To investigate the robustness of the PROFANCY, we repeated all the analyses in two metabolic networks and obtained similar results. Then we applied our approach to Alzheimer's disease (AD) and found that a top ranked candidate was potentially related to AD but had not been reported previously. Furthermore, our method was applicable to prioritize the metabolites from metabolomic profiles of prostate cancer. The PROFANCY could identify prostate cancer related-metabolites that are supported by literatures but not considered to be significantly differential by traditional differential analysis. We also developed a freely accessible web-based and R-based tool at http://bioinfo.hrbmu.edu.cn/PROFANCY.

[1]  Jianjun Yu,et al.  Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression*S , 2008, Molecular & Cellular Proteomics.

[2]  G A Colditz,et al.  Calcium and fructose intake in relation to risk of prostate cancer. , 1998, Cancer research.

[3]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[4]  Chunquan Li,et al.  The Implications of Relationships between Human Diseases and Metabolic Subpathways , 2011, PloS one.

[5]  Neema Jamshidi,et al.  Systems biology of SNPs , 2006, Molecular systems biology.

[6]  O. Demin,et al.  The Edinburgh human metabolic network reconstruction and its functional analysis , 2007, Molecular systems biology.

[7]  C. Sette,et al.  Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. , 2008, Carcinogenesis.

[8]  J. Lindon,et al.  Systems biology: Metabonomics , 2008, Nature.

[9]  J. Kurhanewicz,et al.  Methods for metabolic evaluation of prostate cancer cells using proton and 13C HR‐MAS spectroscopy and [3‐13C] pyruvate as a metabolic substrate , 2009, Magnetic resonance in medicine.

[10]  P. Riederer,et al.  Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease: a human postmortem study. , 2010, Journal of Alzheimer's disease : JAD.

[11]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[12]  G. Hu,et al.  Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. , 2007, Life sciences.

[13]  Jong-Hwan Lee,et al.  Calcium and neostigmine antagonize gentamicin, but augment clindamycin-induced tetanic fade in rat phrenic nerve-hemidiaphragm preparations , 2008, Journal of Anesthesia.

[14]  Igor Goryanin,et al.  Compartmentalization of the Edinburgh Human Metabolic Network , 2010, BMC Bioinformatics.

[15]  H. Mewes,et al.  KEGG spider: interpretation of genomics data in the context of the global gene metabolic network , 2008, Genome Biology.

[16]  T. Montine,et al.  Expression and Activities of Aldo‐Keto Oxidoreductases in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[17]  G. Hu,et al.  Pathological and biochemical alterations of astrocytes in ovariectomized rats injected with d-galactose: A potential contribution to Alzheimer's disease processes , 2008, Experimental Neurology.

[18]  R. Guimerà,et al.  Functional cartography of complex metabolic networks , 2005, Nature.

[19]  P. Wood,et al.  The concept of “aldehyde load” in neurodegenerative mechanisms: Cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line , 2007, Brain Research.

[20]  C. Mitchell,et al.  Inositol polyphosphate phosphatases in human disease. , 2012, Current topics in microbiology and immunology.

[21]  P. Hirvikoski,et al.  Sorbitol dehydrogenase expression is regulated by androgens in the human prostate. , 2010, Oncology reports.

[22]  M. Oti,et al.  The modular nature of genetic diseases , 2006, Clinical genetics.

[23]  R. Vessella,et al.  Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells , 2012, Clinical Cancer Research.

[24]  W. Marston Linehan,et al.  Targeting Cancer Metabolism , 2012, Clinical Cancer Research.

[25]  Veena S. Kasture,et al.  International Journal of Research and Development in Pharmacy and Life Sciences Metabolomics: Current Technologies and Future Trends , 2022 .

[26]  M. Kindy,et al.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. , 2011, Journal of Alzheimer's disease : JAD.

[27]  Ian D Wilson,et al.  HPLC-MS-based methods for the study of metabonomics. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  Huimin Lin,et al.  Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism , 2010, Journal of cellular physiology.

[29]  S. Rea,et al.  Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. , 2012, Mass spectrometry reviews.

[30]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[31]  R. Carey,et al.  Adrenal insufficiency. , 1997, Current therapy in endocrinology and metabolism.

[32]  S. Szabó,et al.  Adrenal Gland: Chemically Induced Structural and Functional Changes in the Cortex , 1989, Toxicologic pathology.

[33]  R. Agarwal,et al.  Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. , 2003, Carcinogenesis.

[34]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[35]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[36]  Gopal Singh,et al.  Regulation of prostate cancer cell division by glucose , 1999, Journal of cellular physiology.

[37]  P. Stattin,et al.  1H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples , 2011, Biomarker insights.

[38]  Holly T. Sullivan,et al.  The Prostate 68 : 620 ^ 628 ( 2008 ) TheMetabolitesCitrate , Myo-Inositol , and Spermine Are PotentialAge-IndependentMarkers of Prostate Cancer inHumanExpressed Prostatic Secretions , 2008 .

[39]  J. Gilbert,et al.  Dementia Revealed: Novel Chromosome 6 Locus for Late-Onset Alzheimer Disease Provides Genetic Evidence for Folate-Pathway Abnormalities , 2010, PLoS genetics.

[40]  Bruce J Trock,et al.  Application of metabolomics to prostate cancer. , 2011, Urologic oncology.

[41]  S. Koochekpour Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer. , 2013, Asian journal of andrology.

[42]  Fathi Mohamed Sherif,et al.  Basic aspects of GABA-transaminase in neuropsychiatric disorders. , 1995, Clinical biochemistry.

[43]  G. S. Hassan,et al.  Synthesis and biological evaluation of some substituted-2-N-(5-chloro-2-methoxy-4-methylphenylsulphonyl) glutamic acid derivatives against prostate cancer cell line PC3. , 2013, Chemical & pharmaceutical bulletin.

[44]  Krin A. Kay,et al.  The implications of human metabolic network topology for disease comorbidity , 2008, Proceedings of the National Academy of Sciences.

[45]  G. Lubec,et al.  Carbohydrate handling enzymes in fetal Down syndrome brain. , 2001, Journal of neural transmission. Supplementum.

[46]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[47]  R. Agarwal,et al.  Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. , 2009, Cancer research.

[48]  D. Kell Metabolomics and systems biology: making sense of the soup. , 2004, Current opinion in microbiology.

[49]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[50]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[51]  M. Kivipelto,et al.  Cholesterol as a risk factor for Alzheimer's disease – epidemiological evidence , 2006, Acta neurologica Scandinavica. Supplementum.

[52]  Michael P. Barrett,et al.  MetExplore: a web server to link metabolomic experiments and genome-scale metabolic networks , 2010, Nucleic Acids Res..

[53]  M. Milburn,et al.  Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis , 2014, Pediatric pulmonology.

[54]  Wei Liu,et al.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC , 2012, Proceedings of the National Academy of Sciences.

[55]  P. Robinson,et al.  Walking the interactome for prioritization of candidate disease genes. , 2008, American journal of human genetics.